Back to News
Market Impact: 0.28
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination
Source: reuters.com
Healthcare & BiotechProduct LaunchesCorporate Guidance & Outlook
AstraZeneca and Daiichi Sankyo formed a clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumor types, including lung and breast cancer. The agreement expands development options for the oncology drugs and could support their future commercial positioning, although no clinical efficacy data or financial terms were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AZN0.40
SMMT0.60
More News
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Anthropic warns government attitudes may hurt customer ties, IPO prospectus shows: Reuters
- Your health insurance premiums may take a big jump in 2027 — here's why
- Anthropic to invest $100 million to train AI engineer talent
- Paramount and Warner Bros. Discovery to Merge Into Skydance (SKYD). Will Skydance Achieve David Ellison’s "Quality Storytelling" Vision?
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Discusses Ontario's AI Economy with Minister Stephen Crawford and Supply Ontario CEO James Wallace
- AI Research Tools for SEDAR+, UK and ASX Filings